Press Releases Dr. Reddy's Laboratories Limited NSE India S.E.

Equities

DRREDDY

INE089A01023

Delayed NSE India S.E. Other stock markets 06:29:33 2024-05-09 EDT			5-day change	1st Jan Change
5,877 ^INR	-2.96%		-6.52%	+1.37%

11:25am	India's Alembic Pharma posts higher Q4 profit on strong N.America sales	RE
05-08	Asian Equities Traded in the US as American Depositary Receipts Trend Slightly Lower in Wednesday Trading	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Dr. Reddy’s Q4 & Full Year FY24 Financial Results	05-07	BU
Dr Reddy Laboratories : Q4FY24 Press PPT	05-07	PU
Doctor Reddy's: Fiscal Q4 Earnings Snapshot	05-07	AQ
Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.	05-03	BU
Genentech And Dr. Reddy's Settle BPCIA Rituximab Litigation	04-24	AQ
Dr Reddy Laboratories : . Reddy’s issues voluntary nationwide recall of Sapropterin Dihyochloride Powder for Oral Solution 100 mg due to Sub-potency - Form 6-K	04-23	PU
Dr Reddy Laboratories : Corporate_Governance_Report- March 31_2024	04-22	PU
Dr Reddy Laboratories : . Reddy's launches Condition Management programme ‘DailyBloom™ IBS’, India’s first-ever digital integrated care plan to manage Irritable Bowel Synome - Form 6-K	04-19	PU
Dr Reddy Laboratories : . Reddy's Investor Presentation - Sep 2023	04-12	PU
Dr Reddy Laboratories : . Reddy’s launches ug-free migraine management device Nerivio® in Europe following successful launch in India - Form 6-K	04-10	PU
Dr Reddy Laboratories : Press Release Nerivio (Global) - Dr. Reddy's launches Nerivio in Europe	04-10	PU
Dr. Reddy's subsidiary betapharm, and Theranica launch Nerivio® in Germany to provide patients with drug-free migraine treatment	04-10	AQ
Dr Reddy Laboratories : Bayer and Dr. Reddy’s sign a marketing and distribution agreement for second brand of Vericiguat™ in India - Form 6-K	04-05	PU
Dr Reddy Laboratories : Press Release_Bayer and Dr. Reddy’s sign a marketing and distribution agreement for second brand of Vericiguat™ in India	04-05	PU
Dr Reddy Laboratories : D17 01.54 PR	03-29	PU
Dr Reddy Laboratories : D17 01.52 PR	03-29	PU
Dr Reddy Laboratories : D17 01.41 PR	03-29	PU
Dr Reddy Laboratories : D17 01.32 PR	03-29	PU
Dr Reddy Laboratories : D17 01.30 PR	03-29	PU
Dr Reddy Laboratories : D17 01.29 PR	03-29	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Dr. Reddy's Laboratories Limited NSE India S.E.

Equities

DRREDDY

INE089A01023

Press Releases

Filters